tbuckley/cabot-search huggingface dataset:
AB0321 ADHERENCE TO MEDITERRANEAN DIET AND PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN RHEUMATIC DISEASES
Authors: S. Rekik, S. Nouicer, S. Boussaid, S. Jemmali, S. Rahmouni, K. Zouaoui, H. Sahli, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2022)

Background Rheumatic diseases (RD) are autoimmune inflammatory arthritis. However involvement to other organs can occur and leads to atherosclerosis and cardiovascular (CV) risk factors. Mediterranean diet (MD) has attracted considerable interest because it seems to offer significant benefits to that end. Objectives To evaluate the role of MD in the development of the cardiovascular risk factors in RD. Methods We conducted a cross-sectional study including patients with RA (ACR-EULAR 2010 criteria) or with SA (ASAS 2009 criteria), in remission or in low activity disease and with no history of cardio vascular risk factors before the diagnosis of their RD. Sociodemographic and disease related data were collected: Disease Activity Score (DAS28-CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) and medication. We asked the patients to complete the 14-items MD adherence questionnary. We evaluated the association of adhrence to MD with cardiovascular risk factors: obesity, type-2 diabetes, hyperlipidemia and hypertension. We estimated odds ratios for each cardiovascular risk factors and their 95% confidence intervals. In all analyses, the high adherence category of MD adherence score [10–14) was considered the reference category. Results We included 61 patients (40 women and 21 men) with a mean age of 42.2 ± 1.1 years old [20-66]. Among them, 32.7% belong to urban environment and 26.2% were professionally active. The mean disease duration was 83.2 months [9-180]. The mean DAS28-CRP was 1.2 [0.8-1.9] and the mean ASDAS-CRP was 1.8 [1.1-2.01]. Methotrexate was used by 52.4%, either as monotherapy or combination and biological in 47.6 %. Thirty patients had high adherence to MD (H-MD) and thirty-one had medium or low adherence to MD (L-MD). We found that higher adherence to the MD is inversely associated with the prevalence of each of the four cardiovascular risk factors, results are shown in Table 1. Table 1. Prevalence of cardiovascular risk factors and odds ratio in high adhrence to Mediterranean diet in rheumatic diseases. Prevalence % Odds ratio 95% confidence intervals Obesity 57.4 0.017 [0.03-0.93] Type-2 diabetes 50.8 0.01 [0-0.019] Hyperlipidemia 50.8 0.126 [0.04-0.3] Hypertension 42.6 0.13 [0.43-0.4] Conclusion Our results suggest that the healthy effects of the MD observed in epidemiologic studies are exerted partly through plausible mechanisms: low prevalence of obesity, of type2 diabetes, of hyperlipidemia and of hypertension. Interventional studies may eventually provide stronger evidence. In the meantime, an increasing of knowledge supports the Mediterranean diet as a useful tool in managing individuals with RD, who are at high risk ofcardiovascular diseases. Disclosure of Interests None declared
AB0666 Body composition and physical function as potential prognostic biomarkers in patients with sIBM
Authors: K. Y. Jensen, J. Alcazar, A. N. Jørgensen, P. Aagaard, C. Suetta, L. P. Diederichsen
Journal: Annals of the Rheumatic Diseases (2022)

Background Sporadic inclusion body myositis (sIBM) is an acquired disease within the idiopathic inflammatory myopathy (IIM) spectrum, characterized clinically by progressive muscle atrophy, weakness and often severely impaired physical function leading to Sarcopenia. Despite of this, muscle mass and physical function is not routinely assessed in patients with sIBM. Objectives To investigate muscle mass, muscle power and physical function in patients with sIBM compared to healthy controls. Methods The study was a retrospective analysis of patients with sIBM (sIBM) and healthy age and gender matched controls (CON) from The Copenhagen Sarcopenia Study 1 . Appendicular lean mass (ALM) and skeletal muscle index (ALM/h 2 ) was assessed by DXA (iDXA, GE). Muscle strength and physical function was evaluated by maximal horizontal gait speed (GS), 30-s sit-to-stand test (30s STS) and maximal leg extensor power (LEP) (PowerRig). A linear mixed-effect model for all outcome variables was used for the statistical analysis. A linear mixed-effect model for all outcome variables was used for the statistical analysis, including sex and health condition as fixed factors, and performed using SPSS v20 (Inc., Chicago, Illinois, USA), and the level of significance was set at α = 0.05 using two-tailed testing. Results In total, 22 patients with sIBM (18 men, age 69.8±4.6; 4 women, age 65.0±8.4) and 414 healthy age-matched controls (237 men, age 70.2±4.9; 177 women, age 65.5±5.4) were included. In men, ALM (sIBM: 21.4±3.1; CON: 25.3±3.6) and ALM/h 2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p&lt; 0.05), while there was no differences in ALM (sIBM: 17.4±1.4; CON: 18.0±2.5) and ALM/h 2 (sIBM: 6.8±0.4; CON: 6.6±0.9) in women with sIBM compared to CON. In men, GS (sIBM: 1.05±0.23; CON: 2.20±0.50), 30s STS (sIBM: 6.1±3.8; CON: 17.8± 5.9) and LEP (sIBM: 79.4±57.3; CON: 255.8±81.3) was reduced in sIBM compared CON, respectively (p&lt; 0.05). Likewise in women, GS (sIBM: 1.27±0.42; CON: 2.16±0.51), 30s STS (sIBM: 7.0±4.8; CON: 18.5±5.9) and LEP (sIBM: 76.5±23.4; CON: 163.7±51.6) was reduced compared CON, respectively (p&lt; 0.05). Conclusion The present data demonstrate that muscle mass and physical function are reduced in patients with sIBM compared to healthy counterparts. Although data from larger studies are warranted, it may indicate that assessment body composition and physical function can be used as prognostic tools in these patients. References [1]Suetta et al, J Cachexia Sarcopenia Muscle 10(6):1316-1329, 2019 Disclosure of Interests Kasper Yde Jensen: None declared, Julian Alcazar: None declared, Anders Nørkær Jørgensen Employee of: Currently employed at Ascendis Pharma, which do not produce drugs/devices used in rheumatology, Per Aagaard: None declared, Charlotte Suetta: None declared, Louise Pyndt Diederichsen: None declared
AB0094 DENDRITIC CELLS AS TARGETS OF PATHOGENETIC THERAPY FOR AUTOIMMUNE DISEASES
Authors: Y. Kurochkina, M. Korolev, E. Letyagina, A. Akimova, N. Banshhikova, V. Omelchenko, Y. Ubshaeva
Journal: Annals of the Rheumatic Diseases (2022)

Background Dendritic cells (DCs) are known to contribute to the pathogenesis of autoimmune diseases through presentation of cartilage glycoprotein, production of proinflammatory cytokines and activation of Th1/Th17 responses. DCs are a heterogeneous population and can be divided into groups: myeloid (mDCs) and plasmacytoid (pDCs). DCs can induce both immune response and tolerance. Objectives The study is aimed at investigating the subpopulations of peripheral blood DCs (myeloid and plasmacytoid) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpa) under disease-modifying antirheumatic drugs (DMARDs) treatment as a target of pathogenic therapy. Methods There are thirty patients were included in the study. Twenty patients with early RA (ACR/EULAR criteria, 2010, duration of the disease up to 12 months,) and ten patients with axSpa (ASAS criteria) were recruited. RA patients received methotrexate, leflunomide, sulfasalazine or their combination. All patients received NSAID in combination with conventional synthetic DMARDs. Analysis of the content of the B-lymphocytes, myeloid and plasmacytoid DCs was carried out by flow cytometry. B-lymphocytes, subtypes of peripheral blood DCs were characterized by the following phenotypes: myeloid DCs (CD3-CD14-CD19-HLA-DR + CD11c + CD123-), plasmacytoid DCs (CD3-CD14-CD19-HLA-DR + CD11c-CD123 +), B-lymphocytes (CD19 +). Analyses were performed before treatment and 6 months later. Results RA patients were characterized by high activity of the disease (DAS28=5.46). At the beginning we revealed significant increasing of the population of myeloid DCs (1.6%) and B-lymphocytes (5.4%). No significant differences were observed in the number of plasmacytoid DCs. After 6 months of treatment, most of the patients had a decrease in the activity of the disease (DAS28=3.5vs5.46, p=0.05, n=12) coupled with a significant decrease mDCs (0.85 vs1.6%, p=0.03) and B-cells (4.2 vs 5.4%, p=0.05). In the remaining patients (n=8), there was no clinically significant improvement (DAS28=4.96) or differences in mDCs (1.45 vs1.6%) and B-cells (5.0vs5.4%). Six months later, there was a decrease in ASDAS activity among axSpa patients (2.56 vs 2.09). We were revealed no differences in amount in mDCs between RA and axSpa patients (1.4 vs 1.6%). After 6 month of investigation we detected decreasing mDCs (1.4 vs 0.9%, p=0.05). We have also found a decrease in B lymphocytes among axSpa patients (5.1 vs 4.1%) that is consistent with some authors’ data on B lymphocytes in spondyloarthritis pathogenesis. Conclusion Reduction in the number of DCs in the context of treatment combined with reduced activity of diseases confirm the role of DCs in the pathogenesis of autoimmune diseases. In addition, probably being a target of pathogenetic therapy, they can serve as a marker of a good clinical response to the therapy. Disclosure of Interests None declared
AB0970 What is the effect of intra-articular injections of glucocorticoids in real clinical practice?
Authors: V. Nesterenko, A. Karateev, M. Makarov, E. Bialik, S. Makarov, V. Bialik, M. Nurmukhametov, A. Roskidailo, N. Burikov, V. Kuznecov
Journal: Annals of the Rheumatic Diseases (2022)

Background Intra-articular injections of glucocorticoids (IAI GC) are widely used in the complex therapy of rheumatic diseases (RD). However, there are relatively few modern data on their efficacy and safety in real clinical practice. Objectives To evaluate the effectiveness of IAI HA in RD in clinical practice. Methods The study group consisted of 290 patients with RD, mainly osteoarthritis (OA) and rheumatoid arthritis (RA) (69.0% of women, age 55.6 ± 12.6 years), who underwent IAI GC in the knee joint. The indications for IAI were determined by the attending physicians. The control consisted of 112 patients with OA (71.4% of women, age 59.3 ± 14.6 years), who underwent a course of IAI of hyaluronic acid (HA). The result of treatment was assessed after 2 weeks, 1 and 3 months. according to a telephone survey. Results After 2 weeks, 1 month. and 3 months. after IAI GC, the severity of pain during movement decreased (numerical rating scale, NRS 0-10, Me [25%; 75%]) from 6.0 [4.0; 8.0] to 1.0 [0; 2.0], 2.0 [1.0; 4.0] and 2.5 [1.0; 4.0], respectively (p &lt;0.001). After 3 months. the number of patients with no / mild pain (&lt;4 according to the NRS) was 63.8%, with a complete / almost complete absence of pain (≤1 by the NRS) - 30.3%. The effect of HSI HA was higher in RA than in OA: the dynamics of pain after 3 months. -4.0 [-2.0; -6.0] and -2.0 [-1.0; -5.0], p = 0.003. In OA, the effect of HAI HA and HA did not differ: the dynamics of pain after 3 months. was -2.0 [-1.0; -5.0] and -3.0 [-1.0; -5.0] p = 0.869. There were no serious adverse reactions in IAI. Conclusion IAI GC are an effective and fairly safe method of short-term treatment of synovitis in RD. Disclosure of Interests None declared
AB0059 Src-LIKE ADAPTOR PROTEIN DEFICIENCY DOSE-DEPENDENTLY PROTECTS MICE AGAINST COLLAGEN-INDUCED ARTHRITIS
Authors: P. Királyhidi, N. Badari, L. Tóth, Z. Pós, N. Lupsa, A. Mocsai, D. Csete, T. Nemeth, E. Buzás, G. Nagy
Journal: Annals of the Rheumatic Diseases (2022)

Background Src-like adaptor protein (SLAP), an adaptor between E3 ubiquitin ligase c-Cbl and the TCR complex, is a negative regulator of T-cell activation. SLAP regulates the expression of the CD3 ζ-chain. In accordance with our previous data, SLAP expression is increased in the CD4+ T-cells of patients with rheumatoid arthritis (RA). Recent data demonstrate that SLAP deficiency can prevent zymosan-induced arthritis in mice. Objectives We investigated the role of SLAP in collagen-induced arthritis (CIA). Methods Homozygous and heterozygous SLAP knock out and wild type (WT) C57BL/6J mice were used. After the isolation of genomial DNA, the genotype of the mice was determined. Then the animals were injected once (primary immunization) or twice (secondary immunization) with type II. collagen, or left untreated (the first injection was applied together with complete Freund’s adjuvant). Mice were monitored twice a week for 70 days, and the severity scores were evaluated. The scores were calculated for each limb (1 limb score: 0=no swelling; 4=the severe swelling). Results SLAP deficiency provided almost complete protection from the primary immunization of CIA. By contrast secondary immunization led to similar arthritis of the SLAP-KO, heterozygous or WT mice. Conclusion The authors’ present data suggest that SLAP deficiency protects dose-dependently from CIA. Acknowledgements This work was supported by OTKA/NKFIHO NN 111023; OTKA/NKFIHN K 131479. Disclosure of Interests None declared
AB1427 ASSOCIATION BETWEEN HYPERURICEMIA AND OSTEOPOROTIC IN CHINESE ADULTS, A CROSS-SECTIONAL STUDY
Authors: J. Zeng, J. Yang, W. R. Lawrence, C. Pan
Journal: Annals of the Rheumatic Diseases (2022)

Background Hyperuricemia may have a protective role in diseases characterized by high levels of oxidative stress, such as osteoporosis. Previous studies have shown that hyperuricemia is associated with osteoporotic. However, this association is controversial and even yielded conflicting results. Objectives This study investigated the relationship between hyperuricemia and osteoporotic among Chinese adults. Methods The data of cross-sectional study was collected at Guangdong Second Provincial General Hospital in Guangzhou City, China between January 2009 and December 2019. Physical examinations and laboratory measurement variables were obtained from the medical check-up system. The multivariate-adjusted logistic regression model was performed to assess the association between hyperuricemia and osteoporotic. Results A total of 18917 participants (11334 males and 7579 females) were included in this study, with an average age of 46.23 years (SD: 11.67) at baseline. It included 5881 cases of hyperuricemia and 1587 osteoporotic. After adjusted for the confounding factors in logistic regression analysis, we observed a negative significant association between hyperuricemia and risk of osteoporotic (odds ratio [OR],0.852, 95%CI 0.795–0.967; P &lt;0.05). Further stratified analyses showed a negative significant association with the risk of osteoporotic in women (OR,0.787, 95%CI 0.698–0.853; P &lt;0.05), man (OR,0.897, 95%CI 0.786–0.954; P &lt;0.05) and old adults (OR, 0.808, 95%CI, 0.759-0.894; P &lt;0.05). No significant differences in other groups. Conclusion Our study observed participants with hyperuricemia had significantly less osteoporosis. More high-quality research is needed to further support these findings. References [1]Zong Q, Hu Y, Zhang Q, Zhang X, Huang J, Wang T. Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: A meta-analysis of observational studies. Joint Bone Spine. 2019 Jul;86(4):419-427. [2]Wang Y, Zhou R, Zhong W, Hu C, Lu S, Chai Y. Association of gout with osteoporotic fractures. Int Orthop. 2018 Sep;42(9):2041-2047. [3]Veronese N, Carraro S, Bano G, Trevisan C, Solmi M, Luchini C, Manzato E,Caccialanza R, Sergi G, Nicetto D, Cereda E. Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: a systematic review and meta-analysis. Eur J Clin Invest. 2016 Nov;46(11):920-930. [4]Veronese N, Bolzetta F, De Rui M, Maggi S, Noale M, Zambon S, Corti MC, Toffanello ED, Baggio G, Perissinotto E, Crepaldi G, Manzato E, Sergi G. Serum uric acid and incident osteoporotic fractures in old people: The PRO.V.A study. Bone. 2015 Oct;79:183-9. Figure 1. Distribution of hyperuricemia and osteoporotic by gender. Disclosure of Interests None declared
POS1134 THE EFFECT OF ETORICOXIB ON PAIN AND SIGNS OF CENTRAL SENSITIZATION IN PATIENTS WITH OSTEOARTHRITIS
Authors: E. Polishchuk, A. Karateev, V. Amirdzhanova
Journal: Annals of the Rheumatic Diseases (2022)

Background Central sensitization (CS) plays an important role in the development of chronic pain in osteoarthritis (OA). Objectives to evaluate the effect of etoricoxib on pain and signs of CS in patients with OA. Methods 790 patients with OA (knee or hip) were included in an open observational study. Most of them (71.6%) were female, mean age 54.5 ± 13.0 years. All patients received etoricoxib 60 mg/day for 2 weeks. The dynamics of pain was assessed on a numerical rating scale (NRS 0-10), the dynamics of the sign of CS was assessed using the Central Sensitization Inventory (CSI). CSI ≥ 40 was observed in 35.3% of patients. Results After 2 weeks of treatment with etoricoxib, the intensity of pain at movement, at rest and at night decreased by 58.8±24.1%, 69.7±32.6% and 70.1±32.8. There was a decrease in CSI values ​​by 33.1±14.5% (p&lt;0.001), as well as a decrease in the number of patients with CSI ≥40: from 35.3% to 10.3% (p&lt;0.001). There were no serious complications during the treatment. The total number of adverse events was 5.9%, mainly dyspepsia and arterial hypertension. Conclusion Etoricoxib improved pain in OA patients and reduces the severity of signs of CS, supporting the central mode-of-action of the drug. Disclosure of Interests None declared
POS1116 DIETARY INFLAMMATORY INDEX AND KNEE STRUCTURES ON MRI AND PAIN: A PROSPECTIVE COHORT STUDY
Authors: F. Pan, J. Tian, M. Cervo, D. Scott, F. Cicuttini, G. Jones
Journal: Annals of the Rheumatic Diseases (2022)

Background While some individual dietary nutrients/components have been shown to be associated with knee osteoarthritis (OA) progression, the associations of the dietary inflammatory index (DII), which reflects the overall inflammatory potential of a diet, with MRI-detected structural changes and pain have not been investigated. Objectives This longitudinal study aimed to determine whether DII scores are associated with knee structural changes and pain over a 10.7-year follow-up in community-dwelling older adults. Methods This study utilised the data from a prospective population-based cohort study (mean age 63 years, 51% women) in which 1,099, 875, 768 and 563 participants completed assessments at baseline, 2.6, 5.1 and 10.7 years, respectively. T1-weighted or T2-weighted MRI of the right knee was performed to measure cartilage volume (CV) and bone marrow lesions (BMLs) at baseline and 10.7 years. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain questionnaire was used to measure knee pain at all assessments. Baseline energy-adjusted DII (E-DII) scores were calculated using a validated Food Frequency Questionnaire. X-ray was performed to assess radiographic knee osteoarthritis (ROA). Linear, log-binomial regression and linear mixed-effects modelling with adjustments for covariates were used to examine the associations of E-DII with CV loss, BML size increase and knee pain, respectively. Pain trajectories (i.e., ‘Minimal Pain’, ‘Mild Pain’, and ‘Moderate Pain’) were previously identified in this cohort using group-based trajectory modelling [1]. Multi-nominal logistic regression was used to examine the association between E-DII and pain trajectory groups. Results The mean E-DII at baseline was -0.48±1.39. In multivariable analyses, E-DII score was not associated with tibial CV loss and BML size increase [CV loss: β=0.03% per annum, 95%CI -0.01–0.06; BML size increase: relative risk (RR)=0.94, 95%CI 0.84–1.05;]. Higher E-DII was associated with greater pain score over 10.7 years (β=0.21, 95%CI 0.004-0.43) and an increased risk of belonging to ‘Moderate pain’ as compared to ‘Minimal Pain’ trajectory group [relative risk ratio (RRR): 1.19, 95%CI 1.02-1.39] after adjustment for age, body mass index, physical activity, education level, employment, emotional problems, comorbidities, and ROA. Conclusion Higher DII was associated with greater pain score and higher risk of more severe pain trajectory, but not structural changes, suggesting discordance between effects of diet on structural damage and pain, and that targeting pro-inflammatory diets may be beneficial to reduce pain. References [1]Pan F, Tian J, Aitken D, Cicuttini F, Jones G. Predictors of pain severity trajectory in older adults: a 10.7-year follow-up study. Osteoarthritis Cartilage. 2018;26(12):1619-26. Disclosure of Interests None declared
AB1419 PERFORMANCE OF AN EARLY TRIAGE SYSTEM FOR IDENTIFICATION OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES
Authors: X. Baraliakos, I. Redeker, M. Zacharopoulou, S. Tsiami, J. Braun
Journal: Annals of the Rheumatic Diseases (2022)

Background The preselection of patients with suspicion of an inflammatory rheumatic disease is not easy for general practitioners and orthopedists. In countries with a limited number of practicing rheumatologists waiting lists are often long, since a full rheumatologic examination often needs a long consultation time. Objectives To test the performance of an early triage strategy for early identification of patients with inflammatory rheumatic diseases. Methods Prior to the SARS-CoV 2 pandemic, physicians caring for patients contacting a tertiary rheumatologic cente were first contacted by a health-care professional (HPR) who offered an appointment the timing of which was based on the symptoms reported (Step 1). Patients were then seen by a rheumatologist who, within a 10-minute consultation (Step 2), shortly examined the patient to determine the urgency of a planned full work up. The main outcome of the study was the comparison between the initial assessment and the final expert diagnosis (Step 3). Results Within 9 months, physicians caring for 1.180 patients contacted the hospital, 972 of whom kept their appointment (82.4%). Most patients were transferred by GPs (73.1%) and orthopedists (22.1%). The mean time between Step 1 and Step 2 was 10.4 days, while 6.2% of patients were seen within 4 days, 24.4% within 7 days and 69.3% within 12 weeks. Only 36 patients (3.7%) of patients had an already established rheumatic disease. Complaints lasting between 0-4 weeks were reported by 69 (7.1%), of &gt; 4-12 weeks by 100 (10.3%), and of &gt; 12 weeks by 973 (82.6%) patients. Almost 90% of patients reported a pain intensity &gt;4/10 (NRS) for &lt; 2 weeks. An elevated CRP was found in 207 patients (24.5%). Prior treatment with glucocorticoids was reported in 163 (16.8%) and with NSAIDs in 730 (75.1% of) patients. The confirmed diagnosis at Step 3 was rheumatoid arthritis in 127 (13.1%), spondyloarthritis including psoriatic arthritis in 72 (7.4%), systemic diseases including connective tissue diseases in 112 (11.5%), vasculitides in 41 (4.2%), and crystal arthropathy in 38 (3.9%) patients, while 38 (3.9%) had an infection, a malignancy or a differential diagnosis such as Raynaud’s phenomenon or sicca syndrome. Degenerative joint diseases (n=254; 26.1%) and non-inflammatory soft tissue syndromes such as fibromyalgia (n=369; 38%) accounted for more than half of the patients. Conclusion This study describes the performance of a standardized triage system hereby confirming the need for an early identification and preselection of patients with rheumatic musculoskeletal symptoms, including involvement of HPRs in the initial phase of contact. Based on the results, three patients with musculoskeletal complaints had to be examined in order to identify one patient with an inflammatory rheumatic disease. Disclosure of Interests None declared